Douglas Nixon, MB, BS, DPhil

Highlights

1
Trends in neurosciences · 2022
THTeresa Hope Evering LGLi Gan DNDouglas Nixon
PMID: 36588011DOISenior author32 citations
2
Proceedings of the National Academy of Sciences of the United States of America · 2022
NHNathaniel Hupert DNDouglas Nixon
PMID: 35012976PMCID: PMC8784160DOISenior author21 citations
3
JCI insight · 2022
MLMatthew Lewis Bendall JHJasmine H. Francis DNDouglas Nixon
PMID: 35349481PMCID: PMC9090245DOISenior author15 citations

Publications

334

Funding

30 View NIH portfolio on RePORTER ↗

Active

4 grants

MPI
Single cell dark matter in the context of HIV and substance use
NIDA · 2025–2030 · via NIH RePORTER
R01DA063076-02
Co-I
HOPE - HIV Obstruction by Programmed Epigenetics
National Institute of Allergy and Infectious Diseases · 2021–2027 · via University of California, San Francisco· 2 renewals
UM1AI164559-05
KP
REACH: Research Enterprise to Advance a Cure for HIV
National Institute of Allergy and Infectious Diseases · 2021–2027· 2 renewals
UM1AI164565-06
Co-I
Immunologic control of HIV-1 through combination bNAbs and biologics
National Institute of Allergy and Infectious Diseases · 2019–2025 · via Rockefeller University
U01AI145921-02

Completed grants (26)

MPI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment
National Institute on Drug Abuse · 2020–2025
R01DA052027-05
MPI
The Role of Transposable Elements in Healthy Aging and in Alzheimer's Disease
National Institute on Aging · 2022–2024
R56AG078970-01
MPI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
National Cancer Institute · 2021–2024
R01CA260691-03
PI
Novel approaches for relating genetic variation in endogenous retroviruses to function and disease
National Human Genome Research Institute · 2021–2024
R21HG011513-02
PI
Genetic Risk of HIV Acquisition: Mechanisms of Resilience
National Institute of Allergy and Infectious Diseases · 2020–2023
R21AI154956-02
PI
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication
National Institute of Allergy and Infectious Diseases · 2018–2023
UM1AI126617-03
PI
HIV induced anti-cancer HERV immunity in prostate, breast and colon cancers
National Cancer Institute · 2018–2022
R01CA206488-03
Sub-PI
HIV Persistence During Therapy Workshop
National Institute of Allergy and Infectious Diseases · 2019–2020 · via EDJ Associates, Inc.
EDJ 202400-01
PI
Elimination of HIV using HERV specific T cells
National Institute of Allergy and Infectious Diseases · 2018–2020
R01AI076059-11
PI
Endogenous retroelements as modulators and markers of HIV-1 latency
Weill Cornell Medical College · 2019–2020
WCMC 201508-01
PI
Brain-region specific HERV expression
Kings College London · 2019–2019Contract
SRA 192663-01
PI
Innate NKT Cells in HIV Infection
NIAID · 2002–2018 · via NIH RePORTER
R37AI052731-17
PI
A novel APOBEC-based vaccine approach for HIV
NIAID · 2014–2017 · via NIH RePORTER
R33AI093179-05
PI
Protective HIV-Specific CD8+ T Cells in Early HIV Infection
NIAID · 2007–2014 · via NIH RePORTER
P01AI071713-05
PI
A novel APOBEC-based vaccine approach for HIV
NIAID · 2011–2014 · via NIH RePORTER
R21AI093179-03
PI
Protective immunity in HIV Highly exposed but uninfected subjects
NIAID · 2010–2013 · via NIH RePORTER
R21AI087131-02
PI
T Regulatory Cells in HIV Infection
NIAID · 2006–2012 · via NIH RePORTER
R01AI068498-05
PI
Cell Mediated Immunity in HIV Infected Children
NIAID · 2005–2011 · via NIH RePORTER
R01AI060379-05
PI
An endogenous retroelement vaccine against HIV-1
NIAID · 2009–2010 · via NIH RePORTER
R56AI084113-01
PI
NK Cells and HIV Infection
NIAID · 2005–2010 · via NIH RePORTER
P01AI064520-05
PI
Viral Tropism and Immune Control in HIV
NIAID · 2006–2009 · via NIH RePORTER
R21AI065241-03
PI
Innate NKT Cells in HIV Infection
NIAID · 2002–2007 · via NIH RePORTER
R01AI052731-05
PI
T Regulatory Cells in HIV Infection
NIAID · 2004–2007 · via NIH RePORTER
R21AI060407-02
PI
HIV VARIATION AND CROSS CLADE CTL RECOGNITION
NIAID · 1999–2005 · via NIH RePORTER
R01AI046254-06
PI
Cell Mediated Immunity in HIV Infected Children
NIAID · 2004–2005 · via NIH RePORTER
R21AI060379-01
PI
DYNAMICS OF HIV1 SPECIFIC CTL IN HIV1 INFECTION
NIAID · 1999–2005 · via NIH RePORTER
R01AI044595-06

Honors & distinctions

1

Member · American Society for Clinical Investigation · 2003

News mentions

4 View all WCM news ↗

Flu Shots, Measles Vaccines Could Also Help "Flatten the Curve" for COVID-19
January 10, 2022
While the world has celebrated the arrival of highly effective vaccines against COVID-19, new work by researchers at Weill Cornell Medicine and the University of Oxford shows that even unrelated vaccines could help reduce the burden of the pandemic.
Weill Cornell Medicine Awarded $28.5 Million NIH Grant to Lead HIV Cure Research
August 17, 2021
Weill Cornell Medicine has been awarded a five-year, $28.5 million Martin Delaney Collaboratory grant from the National Institutes of Health to lead a multi-institutional effort aimed at finding a cure for HIV.
NIAID Renews Weill Cornell Medicine Grant for Advancing Prevention and Treatment Research for HIV
December 1, 2020
Weill Cornell Medicine has received a renewal of a prestigious grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to continue cutting-edge clinical research into treating and preventing infection with human immunodeficiency virus (HIV).
Weill Cornell Medicine Tackles COVID-19
May 7, 2020
Physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to confront the COVID-19 pandemic, focusing a broad spectrum of expertise on the critical issues the disease is posing to healthcare workers and public health officials.

Mentoring

2 All publications with mentees →